Olivier Jean Bohuon
Director/Board Member at RECKITT BENCKISER GROUP PLC
Net worth: 65 491 $ as of 2024-03-30
Profile
Dr. Olivier Jean Bohuon is an Independent Non-Executive Director at Takeda Pharmaceutical Co., Ltd., a Chairman at LEO Pharma A/S, a Member-Supervisory Board at Virbac SA, a Chairman at Laboratoires Majorelle SAS, a Chairman at OJB Conseil SAS, a Chief Executive Officer & Director at Smith & Nephew A/S (Denmark) and a Member at Académie nationale de Pharmacie. He is on the Board of Directors at Reckitt Benckiser Group Plc, Takeda Pharmaceutical Co., Ltd., Virbac SA, Smith & Nephew A/S (Denmark), Algotherapeutix SAS, Biotech Promise SCA SICAV-SIF and Biotech Promise. Dr. Bohuon was previously employed as an Independent Non-Executive Director by Smiths Group Plc, a Non-Executive Director by Shire Plc, a Chief Executive Officer & Director by Smith & Nephew PLC, a President & Chief Executive Officer by Pierre Fabre SA, a President by Abbott Pharmaceutical, Inc., an Executive Vice President-Pharmaceutical Products by Abbott Laboratories, a Member by Académie des Technologies, a Senior VP-European Commercial Operations by GlaxoSmithKline Plc, and a Director-Marketing & Sales by Roussel Uclaf SA. He received his MBA from École des Hautes Études Commerciales de Paris and a doctorate degree from the University of Paris Jussieu.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-20 | 1,149 ( 0.00% ) | 65 491 $ | 2024-03-30 |
Latest news about Olivier Jean Bohuon
Olivier Jean Bohuon active positions
| Companies | Position | Start |
|---|---|---|
| VIRBAC | Director/Board Member | 2010-12-31 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Director/Board Member | 2019-01-07 |
| RECKITT BENCKISER GROUP PLC | Director/Board Member | 2020-12-31 |
Essex Woodlands Management, Inc.
 Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Consultant / Advisor | 2017-12-31 |
Laboratoires Majorelle SAS
 Laboratoires Majorelle SAS Medical DistributorsDistribution Services Laboratoires Majorelle SAS operates as an independent French pharmaceutical company. Its products include Vitaros, Optilov, Keat range, and Carmex. The company was founded by Guillaume El Glaoui in 2012 and is headquartered in Paris, France. | Chairman | - |
Algotherapeutix SAS
 Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Founder | 2017-12-31 |
| Biotech Promise SCA SICAV-SIF | Director/Board Member | - |
| OJB Conseil SAS | Chairman | - |
| Biotech Promise | Director/Board Member | - |
| ░░░░░ ░░░░░ ░░░░░░ ░░░ ░░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░ ░░ ░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Former positions of Olivier Jean Bohuon
| Companies | Position | End |
|---|---|---|
| ░░░ ░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Olivier Jean Bohuon
| University of Paris Jussieu | Doctorate Degree |
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 7 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| SMITH & NEPHEW PLC | Health Technology |
| GSK PLC | Health Technology |
| RECKITT BENCKISER GROUP PLC | Consumer Non-Durables |
| SMITHS GROUP PLC | Producer Manufacturing |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| VIRBAC | Health Technology |
| Private companies | 15 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Pierre Fabre SA
 Pierre Fabre SA Pharmaceuticals: MajorHealth Technology Pierre Fabre SA is a holding company which engages in the research, development, and production of health and beauty product based on natural and biological active ingredients. It operates through the following divisions: Pharmaceutical, Consumer Health Care, and Dermo-Cosmetics. The Pharmaceutial division focuses on therapeutic products for oncology, urology, women’s health, neuropsychiatry, cardiology, pulmonology, allergology, and rheumatology. The Consumer Health division includes prescription over-the-counter drugs which covers family health, oral care, and natural health care. The Dermo-Cosmetics division comprises skin and hair care products. The company was founded by Pierre Fabre in 1962 and is headquartered in Paris, France. | Health Technology |
| Roussel Uclaf SA | Health Technology |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Finance |
Académie des Technologies
 Académie des Technologies Academie des Technologies engages in the technology industry. The company was founded in December 2000 and is headquartered in Paris, France. | |
| Abbott Pharmaceutical, Inc. | |
Laboratoires Majorelle SAS
Laboratoires Majorelle SAS Medical DistributorsDistribution Services Laboratoires Majorelle SAS operates as an independent French pharmaceutical company. Its products include Vitaros, Optilov, Keat range, and Carmex. The company was founded by Guillaume El Glaoui in 2012 and is headquartered in Paris, France. | Distribution Services |
| Académie nationale de Pharmacie | |
Smith & Nephew A/S (Denmark)
 Smith & Nephew A/S (Denmark) Medical SpecialtiesHealth Technology Smith & Nephew A/S operates as a is a global medical technology business. It specializes in healthcare, medical supplies, medical devices, wound care, orthopaedic reconstruction and sports medicine. The company was founded by Thomas James Smith in 1856 and is headquartered in Horsholm, Denmark. | Health Technology |
| Biotech Promise | Miscellaneous |
| OJB Conseil SAS | |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | Health Technology |
| Biotech Promise SCA SICAV-SIF | |
| Majorelle Topco Ltd. |
- Stock Market
- Insiders
- Olivier Jean Bohuon
